GlaxoSmithKline (GSK) has partnered with Germany-based Immatics Biotechnologies for the development of adoptive cell therapies to treat different cancers.

The partners aim to identify, research and develop T-cell receptor (TCR) therapies primarily for solid tumours. Initially, the companies intend to create autologous cell therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Also, the deal covers an option to use Immatics’ ACTallo technique to add allogeneic cell therapies.

The partners will use TCRs discovered with Immatics’ XCEPTOR TCR platform and meant for two of the company’s targets identified and validated using its XPRESIDENT technology.

Immatics CEO Harpreet Singh said: “By combining Immatics’ world-leading target and TCR discovery platforms with GSK’s advanced manufacturing, development capabilities and a commitment to next-generation TCR-T technologies, both companies are joining forces to enable the development of effective novel therapies for cancer patients with high unmet medical need.”

As part of the strategic collaboration agreement, GSK will make an upfront payment of around $50m to Immatics, which is also eligible for more than $550m in development, regulatory and commercial milestones for each product, along with royalties.

GSK holds an option to add more target programmes to the partnership. Immatics will receive option, milestone and royalty payments for each additional programme.

Immatics will be responsible for developing and validating TCR Therapeutics up to the selection of a clinical candidate.

GSK will then carry out development, manufacturing and commercialisation activities globally, while Immatics may choose to work together on the development one or more TCR Therapeutics.

Earlier this month, GSK collaborated with the Coalition for Epidemic Preparedness Innovations (CEPI) to aid the development of a vaccine against the coronavirus, 2019-nCoV.

GSK will provide access to its pandemic vaccine adjuvant platform technology to help speed-up the development of coronavirus vaccine candidates.